Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.
This is a a dose ranging, multi-center, sham-controlled study to evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking. The study will evaluate safety and efficacy in subjects who have keratoconus.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Riboflavin Ophthalmic Solution and UV-A Irradiation Group 1 / Cohort 1 | Experimental | Riboflavin Solution + Exposure to NXL system to achieve total energy level 3 |
|
| Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 / Cohort 2A | Active Comparator | Riboflavin Solution + Exposure to NXL system to achieve total energy level 1 |
|
| Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 / Cohort 2A | Active Comparator | Riboflavin Solution + Exposure to NXL system to achieve total energy level 2 |
|
| Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 / Cohort 2A | Active Comparator | Riboflavin Solution + Exposure to NXL system to achieve total energy level 3 |
|
| Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 / Cohort 2B | Active Comparator | Riboflavin Solution + Exposure to NXL system to achieve total energy level 1 |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NXL Energy 1 | Combination Product | Riboflavin drops + NXL System to Total Energy Level 1 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Topography | Change in Kmax topography value from baseline | 12 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Distance Uncorrected Visual Acuity (UCVA) | Change in Distance UCVA | 12 Months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marco Armijo | Contact | 562-761-7965 | marmijo@glaukos.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Glaukos Investigative Site | Recruiting | Dothan | Alabama | 36301 | United States | |
| Glaukos Investigative Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007640 | Keratoconus |
| ID | Term |
|---|---|
| D003316 | Corneal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 / Cohort 2B | Active Comparator | Riboflavin Solution + Exposure to NXL system to achieve total energy level 2 |
|
| Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 / Cohort 2B | Active Comparator | Riboflavin Solution + Exposure to NXL system to achieve total energy level 3 |
|
| Placebo Group 2 / Cohort 2B | Sham Comparator | Sham Solution with no exposure to NXL System |
|
| NXL Energy 2 | Combination Product | Riboflavin drops + NXL System to Total Energy Level 2 |
|
| NXL Energy 3 | Combination Product | Riboflavin drops + NXL System to Total Energy Level 3 |
|
| Sham Treatment | Combination Product | Sham Drops and No exposure to NXL system |
|
| Recruiting |
| Teaneck |
| New Jersey |
| 07666 |
| United States |
| Glaukos Investigative Site | Recruiting | Westerville | Ohio | 43082 | United States |